RESUMO
Antioxidant therapies are of interest in the prevention and management of ocular disorders such as cataracts. Although an active area of interest, topical therapy with antioxidants for the treatment of cataracts is complicated by multiple ocular anatomical barriers, product stability, and solubility. Entrapment and delivery of antioxidants with poly(lactic-co-glycolic acid) nanoparticles is a possible solution to these challenges, however, little is known regarding their effects in vitro or in vivo. Our first aim was to investigate the impact of blank and lutein loaded PLGA nanoparticles on viability and development of reactive oxygen species in lens epithelial cells in vitro. Photo-oxidative stress was induced by ultraviolet light exposure with cell viability and reactive oxygen species monitored. Next, an in vivo, selenite model was utilized to induce cataract formation in rodents. Eyes were treated topically with both free lutein and lutein loaded nanoparticles (LNP) at varying concentrations. Eyes were monitored for the development of anterior segment changes and cataract formation. The ability of nanodelivered lutein to reach the anterior segment of the eye was evaluated by liquid chromatography coupled to mass spectrometry of aqueous humor samples and liquid chromatography coupled to tandem mass spectrometry (targeted LC-MS/MS) of lenses. LNP had a minimal impact on the viability of lens epithelial cells during the short exposure timeframe (24 h) and at concentrations < 0.2 µg LNP/µl. A significant reduction in the development of reactive oxygen species was also noted. Animals treated with LNPs at an equivalent lutein concentration of 1,278 µg /mL showed the greatest reduction in cataract scores. Lutein delivery to the anterior segment was confirmed through evaluation of aqueous humor and lens sample evaluation. Topical treatment was not associated with the development of secondary keratitis or anterior uveitis when applied once daily for one week. LNPs may be an effective in the treatment of cataracts.
Assuntos
Administração Tópica , Catarata , Luteína , Nanopartículas , Copolímero de Ácido Poliláctico e Ácido Poliglicólico , Animais , Luteína/farmacologia , Luteína/administração & dosagem , Copolímero de Ácido Poliláctico e Ácido Poliglicólico/química , Nanopartículas/química , Catarata/tratamento farmacológico , Ratos , Cristalino/efeitos dos fármacos , Cristalino/metabolismo , Espécies Reativas de Oxigênio/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Antioxidantes/farmacologia , Antioxidantes/administração & dosagem , Humanos , Células Epiteliais/efeitos dos fármacos , Células Epiteliais/metabolismo , Humor Aquoso/efeitos dos fármacos , Humor Aquoso/metabolismo , Masculino , Linhagem Celular , Ácido Láctico/química , Ácido Poliglicólico/químicaRESUMO
Rationale: Cataract is the leading cause of blindness and low vision worldwide, yet its pathological mechanism is not fully understood. Although macroautophagy/autophagy is recognized as essential for lens homeostasis and has shown potential in alleviating cataracts, its precise mechanism remains unclear. Uncovering the molecular details of autophagy in the lens could provide targeted therapeutic interventions alongside surgery. Methods: We monitored autophagic activities in the lens and identified the key autophagy protein ATG16L1 by immunofluorescence staining, Western blotting, and transmission electron microscopy. The regulatory mechanism of ATG16L1 ubiquitination was analyzed by co-immunoprecipitation and Western blotting. We used the crystal structure of E3 ligase gigaxonin and conducted the docking screening of a chemical library. The effect of the identified compound riboflavin was tested in vitro in cells and in vivo animal models. Results: We used HLE cells and connexin 50 (cx50)-deficient cataract zebrafish model and confirmed that ATG16L1 was crucial for lens autophagy. Stabilizing ATG16L1 by attenuating its ubiquitination-dependent degradation could promote autophagy activity and relieve cataract phenotype in cx50-deficient zebrafish. Mechanistically, the interaction between E3 ligase gigaxonin and ATG16L1 was weakened during this process. Leveraging these mechanisms, we identified riboflavin, an E3 ubiquitin ligase-targeting drug, which suppressed ATG16L1 ubiquitination, promoted autophagy, and ultimately alleviated the cataract phenotype in autophagy-related models. Conclusions: Our study identified an unrecognized mechanism of cataractogenesis involving ATG16L1 ubiquitination in autophagy regulation, offering new insights for treating cataracts.
Assuntos
Proteínas Relacionadas à Autofagia , Autofagia , Catarata , Cristalino , Peixe-Zebra , Animais , Catarata/metabolismo , Catarata/tratamento farmacológico , Autofagia/efeitos dos fármacos , Proteínas Relacionadas à Autofagia/metabolismo , Cristalino/metabolismo , Cristalino/efeitos dos fármacos , Humanos , Ubiquitinação/efeitos dos fármacos , Riboflavina/farmacologia , Modelos Animais de Doenças , Linhagem CelularRESUMO
ETHNOPHARMACOLOGICAL RELEVANCE: Qiju Dihuang Pill (QDP) is a traditional Chinese medicine prescription for the treatment of eye diseases. Novel literature reports that copper-induced cell death, called as cuproptosis, is a copper-dependent and differs distinctly from other types of cell death. AIM OF THE STUDY: The present study aims to investigate whether QDP could protect lens epithelial cells via alleviating copper-induced death in diabetic cataract. MATERIALS AND METHODS: The different concentration of QDP medicated serum was administrated on high glucose (HG)-induced human lens epithelial cells (HLECs). The copper concentration was tested using Elabscience Copper Assay kit. The proliferation was detected using CCK-8 and EdU assays. The molecular binding was identified using RIP-PCR and luciferase reporter assay. RESULTS: Results indicated that HG culture condition triggered the copper concentration and repressed the proliferation of HLECs. Then, the elesclomol-Cu (Es-Cu) administration up-regulated the copper concentration and inhibited the proliferation, and cuproptosis inhibitor tetrathiomolybdate (TTM) could specifically reverse the consequence. QDP treatment reduced the copper concentration and cuproptosis-related genes (SLC31A1, FDX1). MeRIP-Seq and RIP-PCR confirmed that QDP reduced the stability of SLC31A1 mRNA through m6A modified site, and copper actually synergized the molecular binding efficiency. Rescue assay verified the role of QDP and SLC31A1 on HLECs' cuproptosis characteristic. CONCLUSION: This research identified the protective role of QDP on HG-induced HLECs in DC through decreasing m6A/SLC31A1-mediated cuproptosis in DC. This finding provides novel insights into mechanisms for QDP and sheds light on the multifaceted role of traditional prescription on DC.
Assuntos
Catarata , Proliferação de Células , Cobre , Medicamentos de Ervas Chinesas , Células Epiteliais , Cristalino , Humanos , Células Epiteliais/efeitos dos fármacos , Células Epiteliais/metabolismo , Catarata/tratamento farmacológico , Medicamentos de Ervas Chinesas/farmacologia , Cristalino/efeitos dos fármacos , Cristalino/citologia , Cristalino/metabolismo , Proliferação de Células/efeitos dos fármacos , Complicações do Diabetes/tratamento farmacológico , Glucose/metabolismo , Linhagem Celular , Células CultivadasRESUMO
PURPOSE: Organ fibrosis is a huge challenge in clinic. There are no drugs for fibrotic cataracts treatments in clinic. Nintedanib is approved by the FDA for pulmonary fibrosis treatments. This study aims to investigate the efficacy and mechanism of nintedanib on fibrotic cataracts. METHODS: Drug efficacy was validated through TGFß2-induced cell models and injury-induced anterior subcapsular cataract (ASC) mice. A slit lamp and the eosin staining technique were applied to access the degree of capsular fibrosis. The CCK-8 assay was used to evaluate the toxicity and anti-proliferation ability of the drug. The cell migration was determined by wound healing assay and transwell assay. The anti-epithelial mesenchymal transition (EMT) and anti-fibrosis efficacy were evaluated by qRT-PCR, immunoblot, and immunofluorescence. The inhibition of nintedanib to signaling pathways was certified by immunoblot. RESULTS: Nintedanib inhibited the migration and proliferation of TGFß2-induced cell models. Nintedanib can also repress the EMT and fibrosis of the lens epithelial cells. The intracameral injection of nintedanib can also allay the anterior subcapsular opacification in ASC mice. The TGFß2/ Smad and non-Smad signaling pathways can be blocked by nintedanib in vitro and in vivo. CONCLUSION: Nintedanib alleviates fibrotic cataracts by suppressing the TGFß2/ Smad and non-Smad signaling pathways. Nintedanib is a potential drug for lens fibrosis.
Assuntos
Movimento Celular , Transição Epitelial-Mesenquimal , Fibrose , Indóis , Cristalino , Fator de Crescimento Transformador beta2 , Animais , Indóis/farmacologia , Indóis/uso terapêutico , Cristalino/efeitos dos fármacos , Cristalino/patologia , Fator de Crescimento Transformador beta2/metabolismo , Transição Epitelial-Mesenquimal/efeitos dos fármacos , Camundongos , Movimento Celular/efeitos dos fármacos , Fibrose/tratamento farmacológico , Humanos , Proliferação de Células/efeitos dos fármacos , Linhagem Celular , Transdução de Sinais/efeitos dos fármacos , Catarata/tratamento farmacológico , Camundongos Endogâmicos C57BL , Células Epiteliais/efeitos dos fármacos , Modelos Animais de Doenças , Antifibróticos/farmacologia , Antifibróticos/uso terapêutico , MasculinoRESUMO
ETHNIC PHARMACOLOGICAL RELEVANCE: Cataract is the most common cause of blindness worldwide, a visual disorder caused by a clouded lens that seriously affects People's Daily lives. Age-related cataract (ARC) is the most common type of cataract due to long-term combined effects of many factors, and its pathogenesis is varied. At present, the surgery is the main treatment for cataracts, but it is still limited to the prevention, treatment of early cataracts and the postoperative complications care. While, its drug treatments are still in the stage of exploration and research. Traditional Chinese Medicine (TCM), a unique resource in China, is conceived under the guidance of traditional Chinese medicine theory and has little toxicity and side effects, but it has made great progress in the treatment and prevention of ARC. AIM OF THIS REVIEW: This review presents an overview of the pathogenesis of ARC in both traditional and modern medicines and summarizes the history and therapeutic effect of TCM on ARC including their formula, crude drugs and active components, and also the other auxiliary methods. METHODS: A number of recognized databases like SciFinder, PubMed, Science Direct, Google Scholar, and China National Knowledge Infrastructure (CNKI) were extensively explored by using keywords and phrases such as "cataract", "age-related cataract", "traditional medicine", "ethnopharmacology", "herbs", "medicinal plants", or other relevant terms, and the plants/phytoconstituents that are evaluated in the models of age-related cataract. As well as the current TCM adjuvant therapy used in the clinical treatment were summarized. RESULTS: TCM revealed to plays an active role in treating age-related cataract, via multi-pathway and multi-target, and can treat or delay ARC by inhibiting abnormal glucose metabolism, antioxidant damage, inhibiting LEC apoptosis, and so on, which is in concordance with the good effects of the global use of TCM in clinical application. Concerning the early prevention and treatment of cataract and postoperative complications, TCM and auxiliary methods remain to achieve better clinical effects. CONCLUSION: ARC belongs to the category of "Yuan Yi Nei Zhang" in TCM theory, showing that there are many causes of ARC including aging, and kidney-yang, spleen, sperm and blood deficiencies. At the same time, the viscera gradually decline, as well as yin or yang progressively become weak, especially in the elder people. So, TCM could be mainly based on liver, kidney, and spleen syndrome differentiation, personalizing diagnosis and treatment, following multiple targets, regulating fundamentally yin and yang, and thus justifying the advantages of Chinese medicine in the prevention and treatment of ARC.
Assuntos
Catarata , Medicamentos de Ervas Chinesas , Masculino , Humanos , Idoso , Medicina Tradicional Chinesa , Medicamentos de Ervas Chinesas/farmacologia , Sementes , Catarata/tratamento farmacológico , Catarata/prevenção & controle , Complicações Pós-Operatórias/tratamento farmacológicoRESUMO
PURPOSE: To compare the safety and efficacy parameters of intravitreal ranibizumab vs intravitreal dexamethasone (IVD) in the treatment of patients with naïve diabetic macular edema (DME) in terms of best-corrected visual acuity (BCVA), central macular thickness (CMT), and possible complications like intraocular pressure (IOP) rise and cataract progression. METHODS: A hospital-based prospective and comparative study of naïve DME patients was conducted between November 2020 and October 2021 with a minimum follow-up (F/U) period of 6 months. Thirty phakic patients received one dose of IVD implant (Group A) and the other 30 (Group B) received three consecutive monthly doses of ranibizumab. The main exclusion criteria were steroid responders and the presence of ocular inflammation. RESULTS: The mean pre-injection CMT in Group A was 405µ and reduced to 297.07µ at 3 months and 278.35µ at 6 months. Mean increase in logMAR BCVA was 0.55. The mean pre-injection IOP was 16.28 and 17.64 mm of Hg at 6 months. In Group B, the mean pre-injection CMT was 401.07µ and reduced to 276.1µ at 3 months and 292.9µ at 6 months. Mean BCVA increased to 0.37. The mean pre-injection IOP was 17.28 mm Hg and 16.42 mm Hg at 6 months. There was no significant progression of cataract in both groups. CONCLUSION: The mean decrease in CMT was comparable in both the groups at 6 months F/U with an improvement of BCVA with no significant IOP fluctuation or cataract progression. Hence, IVD appears to be noninferior to ranibizumab in the treatment of naïve DME.
Assuntos
Catarata , Diabetes Mellitus , Retinopatia Diabética , Edema Macular , Humanos , Ranibizumab , Edema Macular/diagnóstico , Edema Macular/tratamento farmacológico , Edema Macular/etiologia , Retinopatia Diabética/complicações , Retinopatia Diabética/diagnóstico , Retinopatia Diabética/tratamento farmacológico , Glucocorticoides , Dexametasona , Inibidores da Angiogênese , Estudos Prospectivos , Implantes de Medicamento , Acuidade Visual , Catarata/complicações , Catarata/diagnóstico , Catarata/tratamento farmacológico , Injeções Intravítreas , Estudos RetrospectivosRESUMO
PURPOSE: To investigate if inflammation score (IS), calculated from the cornea, anterior chamber, iris, and vitreous, indicates endophthalmitis severity. METHODS: In a prospective study, consecutive adults with a clinical diagnosis of post-cataract endophthalmitis within 6 weeks of surgery were recruited. Patients were allocated to IS-based primary treatment (IS < 10: intravitreal injection and IS ≥ 10: vitrectomy) and randomized to two intravitreal antibiotics combinations (vancomycin + ceftazidime and vancomycin + imipenem). Undiluted vitreous microbiology work-up included culture susceptibility, polymerase chain reaction, Sanger sequencing, and targeted next-generation sequencing. RESULTS: The average age of 175 people was 63.4 ± 10.7 years and included 52.6% small incision cataract surgery and 47.4% phacoemulsification surgery. Severe endophthalmitis (IS ≥ 20), diagnosed in 27.4% of people, had a shorter time to symptoms (average 5.4 vs 8.7 days; P = 0.018), poorer presenting vision (all ≤ hand motion), higher culture positivity (50% vs 30.7%; P = 0.032), and higher Gram-negative bacterial infection (70.8% vs 46.2%; P = 0.042). For IS ≥ 20 discriminant and Gram-negative infection, Spearman's coefficient was 0.7 [P < 0.0001, 95% confidence interval (CI) 0.59-0.82], with an area under the receiver operating characteristic curve of 0.9 (95% CI 0.85-0.94, P < 0.0001), a Youden index J of 0.74, a sensitivity of 87.2%, and a specificity of 87.5%. The final vision of >20/400 and >20/100 was regained in 50.2% and 29.1% of people, respectively. The susceptibility of common Gram-positive cocci and Gram-negative bacilli was the highest for vancomycin (95.0%) and colistin (88.6%), respectively. NGS detected polymicrobial infection in 88.5% of culture-negative endophthalmitis. CONCLUSIONS: Higher inflammation scores indicated severe disease and Gram-negative infection in post-cataract endophthalmitis.
Assuntos
Catarata , Endoftalmite , Infecções Oculares Bacterianas , Adulto , Humanos , Antibacterianos/uso terapêutico , Catarata/tratamento farmacológico , Endoftalmite/diagnóstico , Endoftalmite/tratamento farmacológico , Endoftalmite/epidemiologia , Infecções Oculares Bacterianas/diagnóstico , Infecções Oculares Bacterianas/tratamento farmacológico , Infecções Oculares Bacterianas/epidemiologia , Inflamação , Complicações Pós-Operatórias/cirurgia , Estudos Prospectivos , Vancomicina/uso terapêutico , Vitrectomia , Corpo Vítreo/microbiologiaRESUMO
PURPOSE: Cataract, which occurs as a result of lens opacification, is one of the most common causes of vision loss. In the literature, deterioration of the antioxidant system due to the increase in reactive oxygen species and oxidant levels is shown among the causes of cataract formation. The aim of this study was to investigate the antioxidant effect of chrysin on steroid-induced cataract development in an experimental chick embryo model using morphological, histological and biochemical parameters. METHODS: Within the scope of the study, 150 specific pathogen free (SPF) fertilized eggs were used. Eggs were divided into 6 groups as control (group 1), corn oil (group 2), hydrocortisone hemisuccinate sodium (HC) (group 3), low dose chrysin (group 4), medium dose chrysin (group 5) and high dose chrysin (group 6). On the 15th day of incubation, Chrysin and HC were applicated to the air sac of the eggs with Hamilton and/or insulin injector. On day 17, the chick embryos were removed from the eggs and the bulbus oculi of the embryos were dissected. Lenses of 9 embryos were used for morpholigical cataract grading in each group, lens of 8 embryos for biochemical analysis and intact eyes of 7 embryos for histological evaluation (TUNEL method). RESULTS: No opacity was observed in any of the lenses in Group 1 and 2. Cataract was observed in all lenses in Group 3. The mean opacity grades in group 3 were statistically significantly higher when compared to group 1 and 2 (p<0.05). The difference between group 6 and group 3 was statistically significant (p<0.05). GSH and TAS levels in the lenses were statistically significantly decreased compared to the control group due to HC application (p<0.05). It was determined that the decreased GSH and TAS levels in the lenses increased in relation to the Chrysin application doses. The increased levels of MDA, TOS, caspase 3 and caspase 9 in the HC group decreased significantly depending to the chrysin doses (p<0.05). In addition, while the rate of apoptotic cells determined by the TUNEL method was statistically significantly higher in the HC administered group than in the control group (p<0.05), it was statistically significantly decreased in the chrysin-administered groups, in relation to the dose of chrysin (p<0.05). CONCLUSIONS: We think that anti-cataract effect of crhysin may be due to the antioxidant and antiapoptotic properties of chrysin. However, more research is needed to clarify the anti-cataract effects of chrysin.
Assuntos
Catarata , Cristalino , Animais , Embrião de Galinha , Antioxidantes/farmacologia , Catarata/induzido quimicamente , Catarata/tratamento farmacológico , Catarata/patologia , Cristalino/patologia , Flavonoides/farmacologia , GlutationaAssuntos
Catarata , Endoftalmite , Humanos , Moxifloxacina , Antibacterianos/uso terapêutico , Fluoroquinolonas/uso terapêutico , Catarata/tratamento farmacológico , Endoftalmite/etiologia , Endoftalmite/prevenção & controle , Endoftalmite/tratamento farmacológico , Antibioticoprofilaxia , Complicações Pós-Operatórias/prevenção & controleRESUMO
Purpose: This study was designed to evaluate the visual and anatomical outcomes after cataract surgery in diabetic patients with different intraoperative therapeutic strategies. Methods: The research design comprised of a multicentric, retrospective, interventional study conducted at 6 centers in Argentina, Brazil, Costa Rica, Puerto Rico, Spain, and Venezuela. We included 138 diabetic patients with at least 6-month follow-up following phacoemulsification and intraocular lens implantation. Best-corrected visual acuity (BCVA) and central subfield thickness were collected at baseline and at 1-, 2-, 3-, and 6-month follow-up. Of these, 42 cases were not treated with any intraoperative coadjuvant medication (Group 1), 59 patients received intraoperative bevacizumab (Group 2) and 37 patients received intraoperative triamcinolone (4 mg/0.1 ml) (Group 3). Results: The mean logMAR [± standard deviation (SD)] BCVA improved from 0.82 (± 0.43) at baseline, to 0.14 (± 0.23) at 6-month follow-up (p<0.001) in Group 1; from 0.80 (± 0.48) to 0.54 (± 0.45) (p<0.001) in Group 2; and from 1.0 (± 0.40) to 0.46 (± 0.34) (p<0.001) in Group 3. The mean central subfield thickness increased from 263.57 µm (± 35.7) at baseline to 274.57 µm (± 48.7) at 6-month follow-up (p=0.088) in Group 1; from 316.02 µm (± 100.4) to 339.56 µm (± 145.3) (p=0.184) in Group 2; and from 259.18 µm (± 97.9) to 282.21 µm (± 87.24) (p=0.044) in Group 3. Conclusion: Diabetic patients may significantly benefit from cataract surgery. This study provides evidence to support the use of intravitreal triamcinolone or bevacizumab at the time of cataract surgery in cases with pre-existent diabetic macular edema or moderate-severe non-proliferative diabetic retinopathy. .
Objetivo: Avaliar os resultados visuais e anatômicos após a cirurgia de catarata em pacientes diabéticos com estratégias terapêuticas intraoperatórias diferentes. Métodos: Estudo multicêntrico, retrospectivo, de intervenção realizado em 6 centros da Argentina, Brasil, Costa Rica, Porto Rico, Espanha e Venezuela. Foram incluídos 138 pacientes diabéticos com pelo menos 6 meses de seguimento após facoemulsificação com implante de lente intraocular. Acuidade visual melhor corrigida (BCVA) e a espessura subcampo central (CST ) foram coletadas no início e em 1, 2, 3 e 6 meses de seguimento. Destes, 42 casos não foram tratadas com qualquer co-adjuvante de medicamentos intra-operatório (Grupo 1), 59 pacientes receberam bevacizumab intraoperatório (Grupo 2), e 37 pacientes receberam triancinolona intraoperatória (4 mg/0,1 ml) (Grupo 3). Resultados: A média logMAR (± desvio-padrão [DP]) BCVA melhorou de 0,82 (± 0,43) no início do estudo, para 0,14 (± 0,23) aos 6 meses de seguimento (p<0,001) no Grupo 1; de 0,80 (± 0,48) para 0,54 (± 0,45) (p<0,001) no Grupo 2; e de 1,0 (± 0,40) para 0,46 (± 0,34) (p<0,001) no Grupo 3. A CST média aumentou de 263,57 µm (± 35,7) na linha de base para 274,57±48,7 µm em 6 meses acompanhamento (p=0,088) no Grupo 1; de 316,02 µm (± 100,4), para 339,56 µm (± 145,3) (p=0,184) no Grupo 2; e de 259,18 µm (± 97,9), para 282,21 µm (±87,24) (p=0,044) no grupo 3. Conclusões: Pacientes diabéticos podem se beneficiar significativamente da cirurgia de catarata. Este estudo parece fornecer evidências para apoiar o uso de triancinolona intravítrea ou bevacizumab no momento da cirurgia de catarata em casos com edema macular diabético preexistente (DME) ou retinopatia diabética não-proliferativa moderada a grave. .
Assuntos
Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Retinopatia Diabética/cirurgia , Implante de Lente Intraocular/métodos , Facoemulsificação/métodos , Inibidores da Angiogênese/uso terapêutico , Anticorpos Monoclonais Humanizados/uso terapêutico , Catarata/tratamento farmacológico , Quimioterapia Adjuvante/métodos , Seguimentos , Glucocorticoides/uso terapêutico , Cuidados Intraoperatórios , Injeções Intravítreas , Edema Macular/tratamento farmacológico , Estudos Retrospectivos , Resultado do Tratamento , Triancinolona/uso terapêutico , Acuidade Visual , Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidoresRESUMO
Las cataratas, una acumulación opaca de proteínas dañadas en el cristalino del ojo, representan la causa principal de disminución visual en aquellas personas de mßs de 65 años de edad. De hecho, la mayoría de las personas en ese grupo de edad por lo menos presentan el inicio de formación de estas. En dicha afección se han identificado varios factores que predisponen su aparición. Se considera la enfermedad como un proceso multifactorial en cuanto a su agente causal. En los últimos años se ha sugerido que los radicales libres y el estrés oxidativo forman parte de este proceso, hecho que se corrobora en muchas ocasiones, pues se ha demostrado que la utilización preventiva de antioxidantes exógenos o la estimulación de los sistemas antioxidantes endógenos retardan la aparición de los principales signos y síntomas de la enfermedad.
Cataracts, an opaque accumulation of damaged proteins in eye lens, are the major cause of visual decrease in those persons aged over 65. In fact, most of persons included in that age group at least have the onset of cataracts. In such affection are identified some factors predisposing its appearance. This disease is considered like a multifactorial process, fact corroborated in many opportunities, since it has demonstrated that the preventive use of exogenous antioxidant or stimulation of endogenous antioxidant systems delays appearance of main signs and symptoms of this disease.
Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Antioxidantes/uso terapêutico , Catarata/classificação , Catarata/etiologia , Catarata/tratamento farmacológico , Estresse Oxidativo/fisiologia , Radicais LivresAssuntos
Humanos , Masculino , Feminino , Lactente , Pré-Escolar , Adolescente , Distribuição por Idade , Artrite Juvenil/complicações , Catarata/etiologia , Glaucoma/etiologia , Uveíte Anterior/etiologia , Corticosteroides/uso terapêutico , Anti-Inflamatórios não Esteroides/uso terapêutico , Catarata/diagnóstico , Catarata/tratamento farmacológico , Técnicas de Diagnóstico Oftalmológico , Glaucoma/diagnóstico , Glaucoma/tratamento farmacológico , Metotrexato/uso terapêutico , Pressão Intraocular/fisiologia , Uveíte Anterior/diagnóstico , Uveíte Anterior/tratamento farmacológicoAssuntos
Humanos , Ácido Ascórbico/uso terapêutico , Antioxidantes/economia , Vitamina E/uso terapêutico , Doença de Alzheimer/tratamento farmacológico , Antioxidantes/uso terapêutico , Catarata/tratamento farmacológico , Catarata/prevenção & controle , Doença das Coronárias/tratamento farmacológico , Doença das Coronárias/prevenção & controle , Custos de Cuidados de Saúde/tendênciasAssuntos
Humanos , Animais , Antioxidantes/uso terapêutico , Catarata/tratamento farmacológico , Estresse Oxidativo , Fatores de Risco , Raios Ultravioleta/efeitos adversos , Ácido Ascórbico/uso terapêutico , beta Caroteno/uso terapêutico , Catarata/etiologia , Catarata/fisiopatologia , Estudos de Coortes , Poluição por Fumaça de Tabaco/efeitos adversos , Estudos Retrospectivos , Vitamina E/uso terapêuticoAssuntos
Humanos , Animais , Cães , Ratos , Catarata/tratamento farmacológico , Diabetes Mellitus/complicações , Aldeído Redutase/antagonistas & inibidores , Inibidores Enzimáticos/uso terapêutico , Nefropatias Diabéticas/tratamento farmacológico , Retinopatia Diabética/tratamento farmacológico , Sorbitol , Hiperglicemia/complicações , Inositol , Doença Crônica , Inibidores Enzimáticos/efeitos adversos , Inibidores Enzimáticos/farmacologiaRESUMO
Se efectua una evaluación de la acción de la bendalina sobre la evolución de la catarata cortical senil o presenil en su etapa inicial